Introduction
Hepatitis C virus infection represents the most common cause of chronic hepatitis with potential evolution into cirrhosis and hepatocellular carcinoma [1] . The infected population appears heterogeneous for age, modalities of infection, and disease duration [2] . To date the standard of care of treatment (SOC) has been pegylated interferon alpha 2a or alpha 2b associated with ribavirin. The main goal of the therapy is the achievement of a sustained virological response (SVR) defined as undetectable HCV RNA 24 weeks after stopping treatment.
b. virological nonresponse is considered when the serum HCV RNA level remains above the limit of detection throughout treatment and is defined as less than 2 log10 decline in HCV RNA between baseline and week 12;
c. partial responders if the reduction of HCV RNA is at least 2 log 10 at 12 weeks but it is still detectable at week 24;
d. relapsers if HCV RNA decreases and remains below the limit of detection (<50 IU/mL) during treatment but becomes detectable after cessation of treatment [6] .
HCV infection is often characterized by extrahepatic associated diseases. HCV is considered a stimulus for B-cell clonal expansion underlying benign and malignant B-cell dyscrasias including a subgroup of B-cells non Hodgkin's lymphomas. In this context, we must consider that HCV infection is also characterized by several extrahepatic manifestations. The most common and well characterized is mixed cryoglobulinemia. This condition, as well as some B-cell non Hodgkin's lymphomas, is the result of B-cell clonal expansion due to viral persistence [7] .
Accordingly, the treatment of HCV chronic infection should be addressed not only to the treatment of chronic liver disease, but also to the prevention of HCV-associated diseases.
It is estimated that 25% of HCC worldwide is related to HCV [8] .
If the rate of response to antiviral therapy increases to 80%, over the next ten years, the treatment of half of HCV-infected persons would reduce cirrhosis by 15%, hepatocellular carcinoma by 30% and death for liver disease by 34%. [9] .
The application of the most effective therapy should be a common strategy to block permanently viral replication and avoid the progression to cirrhosis and the development of hepatocellular carcinoma.
Boceprevir and telaprevir are HCV protease inhibitors, recently approved for antiviral therapy in HCV infected patients, are effective to control the viral replication.
Target of protease inhibitors
HCV genome is a single strand RNA of 9000-9100 nucleotide encoding for three stuctural (C, E1, E2), seven non structural (xlink, NS3, NS4A, NS4B, NS5A, NS5B, p7) and F proteins whose role is unknown [10] (Fig 1) .
HCV replicative cycle involves the translation of the HCV RNA into a single polyprotein that is subsequently cleaved to obtain every single structural and non structural proteins.
NS3 is a serine protease while NS4 serves as cofactor. NS3 and NS4A must be assembled in order to become active in catalyzing the cleavage of the other NS proteins from the HCV polyprotein at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions, a condition required for viral replication.
HCV virions turn over rapidly (with a half-life of about 3 h), and up to 10 12 viruses are produced per day in an infected person [11] . Boceprevir and Telaprevir link to NS3/NS4A enzymatic complex in a covalent and reversible manner to disrupt the processing of the HCV polyprotein.
Even if the protease inhibitors are potent antiviral agent, their administration without interferon and ribavirin is characterized by rapid selection of resistant variants of the virus [12] . Accordingly boceprevir and telaprevir need to be administered in a regimen with pegylatedinterferon and ribavirin, commonly named "triple therapy".
During the initial 2 weeks of triple therapy the viral load decline is rapid and unaffected by ribavirin. However, beyond 2 weeks, viral breakthrough occurs if ribavirin is not administered. After 12 weeks, breakthrough occurs in 24% of patients treated with peg-interferon and telaprevir.
Ribavirin also affects the rate of viral relapse. In regimens without ribavirin, relapse occurs in 48% of patients as compared to 14-30% of patients treated with ribavirin [13] .
Management of antiviral therapy in naive patients
Three trials (SPRINT-2, ADVANCE, ILLUMINATE) examined the efficacy of boceprevir and telaprevir in naïve patients.
Telaprevir obtained a SVR rate of 75% as compared to 44% of the SOC with peg-interferon plus ribavirin.
The schedule includes triple therapy (telaprevir + peg-interferon + ribavirin) for the first 12 weeks and peg-interferon+ribavirin for additional 36 weeks (fig 3) . Telaprevir is administered at the dose of 750 mg thrice daily.
The tablets should be taken with high fat (>20 g) meal or snack for optimal adsorption (table 2).
Patients with undetectable HCV RNA at week 4 (rapid virological response, RVR) and 12 (extended rapid virological response, eRVR) can stop therapy after 24 weeks of treatment (response-guided therapy, RGT) [14] .
In the contrast, telaprevir should be stopped when:
a. HCV RNA is more than 1000 UI/ml at week 4 or 12 or Boceprevir was differently studied in black and non-black populations.
The SVR rate was 53% and 68% in black and not-black population, respectively.
Boceprevir requires a "lead-in" phase with peg-interferon and ribavirin for 4 weeks and triple therapy (boceprevir + peg-interferon + ribavirin) for 24 or 32 weeks and again a dual therapy with peg-interferon and ribavirin for the last 4 weeks (fig 4) .
The lead-in in phase is useful in naïve patients to assess the responsiveness to peg-interferon and ribavirin.
In fact, lower SVR rates and development of boceprevir-resistant mutants are more common in patients with HCV RNA reduction less than 1 log 10 at week 4 independently from the treatment scheme [15] .
The recommended dose of boceprevir is 800 mg thrice daily. Meal seems not influence the absorption as much as observed in telaprevir regimens.
In patients with RVR after the "lead-in" phase, SOC is still recommended since SVR is observed in 88% after 48 weeks of therapy [16] .
Accordingly to the response-guided therapy, RGT, patients treated with boceprevir with undetectable HCV RNA at weeks 8 and 24 can stop therapy after 36 weeks of treatment.
If HCV RNA is detectable at week 8, the treatment should continue to 48 weeks.
Boceprevir should be stopped when:
a. HCV RNA is more than 100 UI/ml at week 12 or b. HCV RNA is detectable at week 24.
Management of antiviral therapy in null responders
Retreatment of null responders with peg-interferon and ribavirin is effective in less than 5% of patients [17] .
Telaprevir increases SVR to 31%.
The schedule requires 48 weeks of treatment, with the first 12 weeks of triple and the remaining 36 weeks with peg-interferon and ribavirin.
The stopping rules are the same of naïve patients.
Boceprevir trials did not include null responders and, to date, it is not recommended in such patients.
Management of antiviral therapy in partial responders
Retreatment of partial responders with SOC is effective in 7-15% of patients [17, 18] .
Triple therapy with boceprevir or telaprevir may increase the rate of SVR to 52% and 57%, respectively.
Response-guided therapy is not recommended since 48 weeks are commonly requested.
Management of antiviral therapy in relapsers
Retreatment of relapsers with SOC induces a SVR in less than 1/3 of patients [17, 18] .
Telaprevir is administered for the first 12 weeks and SOC for the further 36 weeks with a SVR rate of 86%.
Boceprevir requires the "lead-in" phase of SOC and triple therapy for the additional 44 weeks with a SVR of 75%.
If HCV RNA is not detected at weeks 8 and 24, the therapy may be stopped at week 32. Blood count should be monitored during the first 4 weeks to identify those who will need support.
STUDY
In patients treated with boceprevir, SVR has been observed more frequently in those who develop anaemia [19] .
Administration of subcutaneous alpha-erythropoietin 40.000 UI once a week is effective in controlling anaemia induced by peg-interferon and ribavirin as well as protease inhibitors trying to maintain the blood level around 100 g/L.
If ineffective, ribavirin may be reduced and blood transfusion considered.
It has been reported that, in triple therapy regimen, ribavirin may be safely reduced without affecting the SVR rate.
When this strategy is insufficient and anaemia becomes more severe, blood transfusion is required.
Neutropenia occurs in 70-80% of patients treated with triple therapy and this is more commonly observed in those developing anaemia [20] . Table 4 . Management of haematological side effects during triple therapy.
The adverse effects described during peg-interferon and ribavirin therapy such as rush, flu like and gastrointestinal symptoms are more commonly observed during triple therapy.
Fatigue, nausea, dysgeusia, chills, insomnia, alopecia, diarrhoea, decreased appetite, irritability, vomiting, arthralgia, dizziness, dry skin rash, asthenia, dyspnoea on exertion are more common during boceprevir [21] . In particular, dysgeusia affects almost 50% of patients.
Telaprevir induces hyperuricemia, fatigue, pruritus, diarrhoea, vomiting, haemorrhoids, anorectal discomfort, dysgeusia and anal pruritus relative to patients on standard of care.
Cutaneous rash is the less tolerated side effect of telaprevir. Fortunately, more than 90% of such events is mild or moderate and does not progress. Discontinuation occurs only in 6% of cases [22] . Oral antihistamines or a topical steroid is effective in controlling symptoms.
Moderate rash may associate with pruritus or mucosal involvement. When more than 50% of the body surface is involved or vesicles, bullae or ulceration develop, rash is considered severe and telaprevir should be stopped; peg-interferon and ribavirin can be continued for additional 6-7 days. If the rash does not improve, all drugs should be stopped and hospitalization and appropriate therapy is required [23] .
Haemorrhoids, anal pruritus, anorectal discomfort and anal burning observed during telaprevir may be managed with topic steroid or local lidocaine.
Life threatening or systemic reaction (Steven-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms -DRESS, erythema multiforme-EM) are rarely observed (refer to the specific chapter for details). 
Drug interactions
Boceprevir and telaprevir are metabolized via the cytochrome P4503A pathway. They are potent inhibitors of CYP3A4 and also substrates and inhibitors of the drug transporter Pglycoprotein (P-gp).
Boceprevir and telaprevir availability depends on Child-Pugh but not on renal function.
Concentration of boceprevir in serum increases of 30% and 45-60% in patients with Child Pugh B and C, respectively.
Telaprevir is reduced of about 10-15% and 50% in Child Pugh B and C, respectively. Protease inhibitors greatly impact the metabolism of HMG-CoA reductase inhibitors.
Simvastatin and lovastatin are not recommended in patients treated with boceprevir or telaprevir. Atorvastatin should be avoided when telaprevir is administered and a lowest dose should be selected in boceprevir treated patients. Pravastatin is metabolized by other pathway and the risk of interaction is not completely defined. Rosuvastatin may be safely administered, even if it has not been specifically addressed in the trials. Both boceprevir and telaprevir may reduce contraceptive efficacy of ethinyl estradiol. Moreover, boceprevir can increase plasmatic level of drosperidone while telaprevir reduces norethindrone.
STATINS
Benzodiazepines (triazolam, alprazolam, flurazepam) may be greatly affected by protease inhibitors and should be avoided until new data are available.
Both boceprevir and telaprevir increase metabolism of escitalopram and its effect may be reduced.
Zolpidem concentration is reduced by of 42% in patients treated with telaprevir as well as trazodone.
Boceprevir and telaprevir reduce the clearance of cyclosporine and tacrolimus. The exposure to cyclosporine increases 4-fold with telaprevir and 3-fold with boceprevir, while tacrolimus plasmatic concentration increases 70-fold after telaprevir administration and 17-fold after Table 6 . Summary of drugs to avoid and drugs to use with caution in combination with boceprevir (BOC) and telaprevir (TPV).
Triple therapy in cirrhotic and liver transplant patients
Cirrhosis increases morbidity and mortality and reduces SVR [24] .
Clinical efficacy in cirrhosis has been investigated in phase 3 trials (ADVANCE, ILLUMI-NATE, REALIZE, RESPOND-2, SPRINT-2).
SVR is reached in 33% -46% after 48 weeks of peg-interferon and ribavirin. [25, 26] The addiction of a protease inhibitor improves the SVR to 50% [26] . In these cases, 48 weeks of treatment are commonly required.
In relapsers, the addition of a protease inhibitor increases SVR to 87%.
Practical Management of Chronic Viral Hepatitis
In partial responders SVR rate is lower (34% with triple therapy and 20% in peg-interferon and ribavirin schedule)
There are no benefits in cirrhotic null responders with by using telaprevir (14% vs 10%) [27] .
The relapse rate remains high and side effects are too frequently observed in cirrhotic patients [24] .
Until now, protease inhibitors are not approved for patients with liver transplantation for the interactions with immunosuppressive drugs [12] .
Genetics and triple therapy
Interleukin 28B (IL28B) polymorfisms impacts the response to peg-interferon and ribavirin. Table 8 . Response rate according to IL28B genotype (rs12979860) in treatment-naive North American G1 HCV patients receiving 48 week peg-interferon alpha plus ribavirin. Genotype C/C achieves SVR in 69% (good response).
The rs12979860 polymorphism has three possible genotypes (C/C, C/T, T/T), with C/C showing 2.5 or grater rate of SVR during therapy with peg-interferon and ribavirin.
The rs 8099917 polymorphisms has G/G, G/T, T/T genotypes. T/T genotype associates with higher SVR.
In G1 infected naive-patients eligible for antiviral therapy, the response after the "lead-in" phase and IL28B genotype are the most powerful predictors of response. In selective cases, when the benefit versus risk ratio is difficult to define IL28 may support the final decision. 
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